Nature Medicine study shows Peregrine's bavituximab can cure lethal virus ... ( TUSTIN Calif. November 23 2008 -- Pe...)

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

Date:12/23/2008

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

Bavituximab is in clinical trials for the treatment of hepatitis C virus (HCV) infection and in preclinical development for the treatment of viral hemorrhagic fevers under a contract worth up to $44.4 million with the bioterrorism program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections.

"Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new class of drugs for the treatment of life-threatening viral infections," said study co-author Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center and a scientific advisor to Peregrine. "By targeting a property of the host cell rather than the virus itself, anti-PS antibodies have the potential to treat a range of viral infections, and they should be less susceptible to the viral mutations that contribute to the development of drug resistance."

In the research reported today, scientists at UT Southwestern assessed the activity of bavituximab in animal models of two lethal viruses--cytomegalovirus and Lassa fever virus, a hemorrhagic fever virus that is listed as a class A bioterrorism agent by the CDC. Bavituximab showed potent anti-viral activity in both models.

Dr. Melina Soares, lead study author and UT Southwestern instructor of pharmacology, commented, "Recent non-affiliated research has further confirmed that exposed PS has immunosuppressive properties and is also clarifying its involvement during vi
'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related biology technology :

1. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
2. Professor Straufs research is Nature Photonics’ cover article
3. Attagenes Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
6. Tree branching key to efficient flow in nature and novel materials
7. New yeast trick for eating favorite food: Details in Nature paper
8. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
9. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
10. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
11. Genetic clock makers at UC San Diego publish their timepiece in Nature

Post Your Comments:

(Date:11/30/2009)...ewswire/ -- Acuo Technologies, developers of high-...a migration tools and services, today announced co...new Vendor Neutral Archive (VNA), providing the fo...k of hospitals, clinics and affiliates. ,, The ...es DICOM Services Grid(TM) Software. The Acuo VNA...

(Date:11/30/2009)...v. 30 Good Publication Practice 2 ...n of company-sponsored medical research, has been ...nal (BMJ). "The publication of GPP2 in BMJ is stro...ort and guidance for industry sponsored research a...viewed medical literature," said Chris Graf, Assoc...

(Date:11/30/2009)...ANGELES, Nov. 30 /PRNewswire-Asia-FirstCall/ --,Ch...ard: CYXN; ,China Yongxin,Pharmaceuticals, or ,the...d,retailer of pharmaceuticals in Northeastern Chin...r distribution of medicines on the Essential Drug ...ormalized the nation,s Essential Drug,List which c...

(Date:11/30/2009)...roviding smart and efficient software to the precl... evolutionizing work-from-home histopathology by u...ware used by 8 of the Top 10 Pharmaceutical Compan...squo; basis. , Mount Arli...ounced another evolution in the histopathology rea...

Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2 Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3 ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2 ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3 Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2 Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3

[0] Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics [1] ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ [0] China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List [0] Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS

...Calif., Feb. 9 Beckman Coulter, Inc. (NYSE: BEC...er of products that simplify, automate and innovat...th quarter and year ended December 31, 2008 result....3 million, up 2.8%, on robust sales to Clinical D...e in Life Sciences revenue. In constant currency,...

...Calif., Feb. 9 Beckman Coulter, Inc. (NYSE: BEC...lared a quarterly dividend payout of seventeen cen...payable on March 6, 2009 to all stockholders of re... the 79th consecutive, quarterly payout of dividen...rnh/20031202/BECLOGO ) , , Beckman Coulter, Inc.,...

... M2S Inc., a global provider of image man... device clinical trials, announced today that the ...ss how state-of-the-art image management can enhan...assurance services for bone mineral density trials...sition measurements with DXA. , ...

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert

(Date:12/1/2009)...nnas aren,t just for listening to the radio anymor...GPS devices. Research from North Carolina State Un...esign creating shape-shifting antennas that open ...rom public safety to military deployment. , Mode...but there are limitations to how far they can be b...

(Date:11/30/2009)...rst comprehensive review of the state of Antarctic...mate system is published this week (Tuesday 1 Dece...earch (SCAR). The review - Antarctic Climate Chan...ch from the icy continent, identifies areas for fu... questions that policy makers have about Antarctic...

(Date:11/30/2009)... of scientists from The Forsyth Institute, the Uni...the Wadsworth Center, have used state-of-the-art t...of Treponema pallidum, the bacterium which causes ...e of the bacteria can now be shown in three dimens...thogen and reveals previously unknown features, wh...

Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2 First comprehensive review of the state of Antarctica's climate 2 Scientists gain new understanding of disease-causing bacteria 2 New Shape HF Cardiopulmonary Testing System to be on Display at the Heart Failure Society of America 13th Annual Scientific Meeting September 13 16 56506 1 New Shape HF Cardiopulmonary Testing System to be on Display at the Heart Failure Society of America 13th Annual Scientific Meeting September 13 16 56506 2 New Shape HF Cardiopulmonary Testing System to be on Display at the Heart Failure Society of America 13th Annual Scientific Meeting September 13 16 56506 3 First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 56504 1 First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 56504 2 First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 56504 3 Cell Therapeutics Inc s 28CTI 29 Rodman 26 Renshaw Healthcare Conference Presentation to be Webcast 56502 1

[0] Shape shifters: Researchers create new breed of antennas [0] First comprehensive review of the state of Antarctica's climate [0] Scientists gain new understanding of disease-causing bacteria

...prise the forests of the sea, and are responsible ...ins life on Earth including our own. However, unl...are nearly exclusively microscopic in size, and mo...ll in a very early stage of understanding even the...cology. , In a new paper published in Nature , a...

... variations in genes which can result in changes i... be associated with susceptibility to common disea...journal of the Association for Psychological Scien...es from the Karolinska Institutet in Sweden and th... effect of specific polymorphisms on how fear is l...

...rch 10, 2009) -- Virginia Commonwealth University ...chanism the malaria parasite uses to enter human r...t of a vaccine cocktail to fight the mosquito-born...ough bites from mosquitoes. According to the Cente... million and 500 million cases of malaria occur wo...

Other Biology News:A new view of oceanic phytoplankton 2 A new view of oceanic phytoplankton 3 The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2 Researchers identify new way the malaria parasite and red blood cells interact 2

A new view of oceanic phytoplankton The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders Researchers identify new way the malaria parasite and red blood cells interact

Factor Xa Protease from QIAGEN

Mung Bean Nuclease from New England Biolabs

...s for interferons are cytopathic effect inhibition...Sample types include; tissue culture supernatents;... In these assays, one unit is defined as the quant...e the cytopathic effect of viral infection by 50%....

SP6 RNA Polymerase from Roche Applied Science

Biology Products:

Factor Xa Protease from QIAGEN Mung Bean Nuclease from New England Biolabs Pig Interferon Alpha Bioassay Services from PBL InterferonSource SP6 RNA Polymerase from Roche Applied Science

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus ...( TUSTIN Calif. November 23 2008 -- Pe...)